<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02619942</url>
  </required_header>
  <id_info>
    <org_study_id>RELARC</org_study_id>
    <nct_id>NCT02619942</nct_id>
  </id_info>
  <brief_title>Investigate the Radical Extent of Lymphadenectomy of LAparoscopic Right Colectomy for Colon Cancer(RELARC).</brief_title>
  <acronym>RELARC</acronym>
  <official_title>A Multicenter, Prospective, Randomized Clinical Trial to Investigate the Radical Extent of Lymphadenectomy: D2 Dissection vs. Complete Mesocolic Excision, of LAparoscopic Right Colectomy for Right-sided Colon Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether extended lymphadenectomy (CME) in laparoscopic colectomy could improve
      disease-free survival in patients with right colon cancer, compared with standard D2 radical
      operation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our study design is a two-arm, parallel-group, single-blind randomized clinical trial. The
      enrolled colon cancer patients would be divided into the intervention group (CME group) and
      control group (D2 radical operation group).

      The postoperative adjuvant chemotherapy is determined by the pathological results. For
      patients of stage Ⅲ and patients of stage Ⅱ with unfavorable histologic features, six months
      of adjuvant chemotherapy of XELOX or fluorouracil-based regimen are recommended.

      The postoperative examination should be performed every four months in the first two years
      and every six months in the following three years, to exclude local recurrence and distant
      metastasis.

      Our study is expected to last five years, of which two years for recruiting patients, three
      years for follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 years overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis rate of central lymph node (3rd station)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1072</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>D2 radical operation group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In D2 radical operation group(D2), the mesocolon should be removed and the dissection involves the paracolon and intermediate lymph nodes, which along the feeding vessels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CME group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In complete mesocolic excision group (CME), in addition to D2 dissection, the whole mesocolon, from ascending colon to right half transverse colon, as well as the central lymph nodesmshould be entirely removed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>D2 radical operation</intervention_name>
    <description>In D2 radical operation group(D2), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue.</description>
    <arm_group_label>D2 radical operation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Complete mesocolic excision (CME)</intervention_name>
    <description>In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.</description>
    <arm_group_label>CME group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients suitable for curative surgery 18-75years old

          2. ASA grade I-III

          3. Qualitative diagnosis: a pathological diagnosis of adenocarcinoma;

          4. Localization diagnosis: the tumor located between the cecum and the right 1/3 of
             transverse colon;

          5. Enhanced CT scan of chest, abdominal and pelvic cavity: assessment of tumor stage is
             T2-T4N0 or TanyN+; there is no distant metastasis.

          6. Informed consent

        Exclusion Criteria:

          1. Simultaneous or simultaneous multiple primary colorectal cancer;

          2. Preoperative imaging examination results show: (1) colon cancer of stage T1N0; (2)
             enlargement of lymph node at the root of mesocolon, in which case the D3 radical
             operation must be performed;

          3. Preoperative imaging examination results show: (1) Tumor involves the surrounding
             organs and combined organ resection need to be done; (2)distant metastasis; (3)unable
             to perform R0 resection;

          4. History of any other malignant tumor in recent 5 years, except for cervical carcinoma
             in situ which has been cured, basal cell carcinoma or squamous cell carcinoma of skin;

          5. Patients need emergency operation;

          6. Not suitable for laparoscopic surgery (i.e., extensive adhesion caused by abdominal
             surgery, not suitable for artificial pneumoperitoneum, etc).

          7. Informed consent refusal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi XIAO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lai XU, MD</last_name>
    <phone>+861015810470115</phone>
    <email>xulaipumch@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun-yang LU, MD</last_name>
    <email>lujunyang@pumch.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lai XU</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lai XU, MD</last_name>
      <phone>+861015810470115</phone>
      <email>xulaipumch@163.com</email>
    </contact>
    <investigator>
      <last_name>Yi XIAO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2015</study_first_submitted>
  <study_first_submitted_qc>November 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2015</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>XIAO Yi, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Right colon cancer, Survival, Laparoscopic surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

